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Background: Oral capecitabine achieves a superior response rate with an improved safety profile compared
with bolus 5-fluorouracil–leucovorin (5-FU/LV) as first-line treatment for patients with metastatic colorectal
cancer. We report here the results of a large phase III trial investigating adjuvant oral capecitabine compared
with 5-FU/LV (Mayo Clinic regimen) in Dukes’ C colon cancer.
Patients and methods: Patients aged 18–75 years with resected Dukes’ C colon carcinoma were randomized
to receive 24 weeks of treatment with either oral capecitabine 1250 mg/m2 twice daily, days 1–14 every 21 days
(n = 993), or i.v. bolus 5-FU 425 mg/m2 with i.v. leucovorin 20 mg/m2 on days 1–5, repeated every 28 days
(n = 974).
Results: Patients receiving capecitabine experienced significantly (P <0.001) less diarrhea, stomatitis, nausea/
vomiting, alopecia and neutropenia, but more hand–foot syndrome than those receiving 5-FU/LV. Fewer
patients receiving capecitabine experienced grade 3 or 4 neutropenia, febrile neutropenia/sepsis and stomatitis
(P <0.001), although more experienced grade 3 hand–foot syndrome than those treated with 5-FU/LV
(P <0.001). Capecitabine demonstrates a similar, favorable safety profile in patients aged <65 years or ≥65 years
old.
Conclusions: Based on its improved safety profile, capecitabine has the potential to replace 5-FU/LV as stand-
ard adjuvant treatment for patients with colon cancer. Efficacy results are expected to be available in 2004.
Keywords: Adjuvant treatment, capecitabine, chemotherapy, colorectal cancer
Introduction
Clinical trials have demonstrated that adjuvant treatment
improves outcomes for patients with resected colon cancer. A
pooled analysis of three studies (including 1493 patients) con-
firmed that adjuvant treatment with 5-fluorouracil (5-FU) plus
leucovorin (LV) significantly increased 3-year event-free survival
and overall survival, leading to a 22% reduction in mortality
(P = 0.029) compared with no treatment [1]. In addition, a recent
phase III trial confirmed that 5-FU/LV (Mayo Clinic regimen) is a
more effective adjuvant treatment than 5-FU/levamisole, signifi-
cantly reducing recurrence and achieving superior disease-free
and overall survival [2]. Currently, it is accepted that treatment
with 5-FU/LV for 6–8 months is the standard adjuvant therapy for
Dukes’ C (stage III) colon cancer, with trials showing no differ-
ence in the efficacy of weekly and monthly 5-FU/LV regimens
[3, 4]. Infusional 5-FU/LV is not standard for adjuvant treatment
of colon cancer. The one trial comparing bolus with infusional
5-FU/LV failed to show non-inferiority [5].
Despite the advances afforded by the use of 5-FU/LV, evidence
suggests that there is considerable discrepancy between consensus
recommendations advocating the routine use of adjuvant treat-
ment and its use in the community [6]. In particular, older patients
are less likely to receive chemotherapy, possibly due to physi-
cians’ concerns about increased toxicity in this group. In a German
randomized trial comparing 5-FU/LV with 5-FU/levamisole as
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adjuvant treatment for resected stage III colon cancer, treatment
was prematurely discontinued in 24% of patients, primarily due to
toxicity and lack of compliance [7]. Better-tolerated, more con-
venient and more active chemotherapy is required for the adjuvant
treatment of colon cancer.
In the metastatic setting both a questionnaire-based study [8]
and a randomized, treatment cross-over study [9] indicated that
the majority of patients (84–89%) prefer oral chemotherapy, as
long as efficacy is not compromised. Patients indicated that the
principal reasons for this preference were the avoidance of prob-
lematic i.v. access and the improved convenience of home-based
treatment. In addition, Payne [10] demonstrated that patients’ qual-
ity of life was significantly improved with home-based compared
with hospital-based therapy.
Capecitabine (Xeloda®; F. Hoffmann-La Roche, Basel,
Switzerland) is an oral fluoropyrimidine that generates 5-FU
preferentially in tumor tissue via a three-step enzymatic cascade.
The final step is catalyzed by thymidine phosphorylase, an
enzyme with significantly higher activity in tumor compared with
healthy tissue [11]. Oral capecitabine is effective in the treatment
of metastatic colorectal cancer, offering improved convenience
and patient acceptability compared with i.v. 5-FU/LV. Two large
phase III trials have shown that, as first-line therapy for metastatic
colorectal cancer, capecitabine achieves a superior response rate
and at least equivalent time to disease progression (TTP) and
overall survival compared with 5-FU/LV (Mayo Clinic regimen)
[12]. Capecitabine also demonstrated an improved safety profile
compared with 5-FU/LV [13], with significantly less diarrhea,
stomatitis, nausea, alopecia and grade 3 or 4 neutropenia, leading
to less febrile neutropenia and fewer associated hospitalizations
(P <0.001). Hand–foot syndrome occurred more frequently in the
capecitabine arm than in the 5-FU/LV arm (P <0.001), but this
cutaneous side-effect is never life threatening and can be managed
effectively by treatment interruption and/or dose modification
[13].
Considering the documented high activity, good tolerability and
improved convenience in patients with metastatic disease,
capecitabine has been further evaluated as adjuvant therapy for
colon cancer. This international, multicenter, randomized, open-
label phase III study evaluated capecitabine versus i.v. 5-FU/LV
(Mayo Clinic regimen) as adjuvant therapy for patients with
Dukes’ C colon cancer. The primary objective of the study was to
demonstrate that disease-free survival with capecitabine is at least
equivalent to that achieved with 5-FU/LV (Mayo Clinic regimen).
Secondary end points included overall survival, quality of life,
medical resource utilization and safety. The trial has completed
recruitment of 1987 patients and efficacy results are expected in
2004. We report here the results of the planned safety analysis,
conducted 19 months after the enrollment of the last patient.
Patients and methods
The study was conducted in full concordance with the Declaration of Helsinki
and all of its amendments, or with the laws and regulations of the country in
which the research was conducted, whichever afforded the greater protection
to the individual. Patients gave full informed consent prior to study-specific
screening procedures.
Eligibility criteria
Eligible patients were aged 18–75 years (although some ≥75 years were given
waivers to participate in the study) and had histologically confirmed Dukes’
C colon carcinoma (with at least one positive lymph node) after surgery with
curative intent. Carcinoembryonic antigen (CEA) concentrations were to be
within the normal range. Patients were required to have fully recovered
following surgery and have an Eastern Cooperative Oncology Group (ECOG)
performance status of ≤1 and a life expectancy of at least 5 years.
Patients with evidence of metastatic disease, including tumor cells in ascites
at study entry, were ineligible. Those who had received cytotoxic chemo-
therapy or who had organ allografts, clinically significant cardiac disease,
severe renal impairment or central nervous system disorders were also
excluded. Pregnant or lactating women and sexually active patients unwilling
to practice contraception were excluded.
Study design and treatment
This international, multicenter, randomized, open-label, parallel-group phase
III study was designed to demonstrate that capecitabine achieves at least
equivalent disease-free survival to 5-FU/LV (the Mayo Clinic regimen) when
administered as adjuvant treatment following surgery for Dukes’ stage C colon
cancer. Secondary end points were overall survival, quality of life, medical
resource utilization and safety profile.
Patients were randomized to receive 24 weeks of treatment with either oral
capecitabine 1250 mg/m2 twice daily, given on days 1–14 every 21 days, or i.v.
leucovorin 20 mg/m2 by rapid infusion followed immediately by i.v. bolus
5-FU 425 mg/m2, days 1–5 every 28 days.
After inclusion of 1363 patients, an amendment reduced the capecitabine
starting dose by 25% in patients with moderate renal impairment (estimated
creatinine clearance 30–50 ml/min [14]) based on newly available data [13, 15].
Screening/baseline assessments
Assessments included medical history, a general physical examination, vital
signs, physical measurements, performance status, laboratory tests (hematology,
blood chemistry, pregnancy test, urinalysis and CEA determination) and ECG.
The presence of metastatic disease was excluded by computed tomography
(CT) scan or magnetic resonance imaging (MRI) of abdomen and pelvis and
chest X-ray. A baseline quality of life assessment (QLQ-C30) was also
performed.
Evaluation of safety
This prospectively planned safety analysis was conducted 19 months after
enrollment of the last patient. Adverse events were recorded and graded
according to National Cancer Institute of Canada common toxicity criteria
(NCIC CTC), revised in May 1991. Hand–foot syndrome was graded 1 to 3, as
described previously [16, 17]. Laboratory analyses performed at the beginning
of each cycle included: hemoglobin, white blood and platelet cell counts, total
bilirubin, alanine aminotransferase (ALAT), aspartate aminotransferase
(ASAT), alkaline phosphatase, serum creatinine, potassium, sodium, phosphate,
uric acid and calcium.
Dose modification
The capecitabine and 5-FU/LV (Mayo Clinic regimen) dose modification
schemes have been published in detail [13]. In the 5-FU/LV treatment group,
the dose of leucovorin was not modified, but the 5-FU dose was reduced (to
80% or 70% of the preceding dose) or escalated (to 110% of the preceding
dose) depending upon the occurrence and severity of either clinical adverse
events or hematological/laboratory abnormalities, or their absence in the pre-
ceding treatment cycles. In the capecitabine group, treatment was continued at
the same dose (without interruption or dose reduction) if patients experienced
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toxicities no greater than grade 1 or other toxicities unlikely to become severe
or life threatening (e.g. alopecia). All patients were instructed to interrupt
capecitabine treatment upon the development of moderate or severe toxicity
(grade ≥2), and to immediately contact the clinic for further directions. At a
second occurrence of grade 2 toxicity, or after appearance of grade 3 or 4
toxicity, the capecitabine dose was to be reduced by 25%. In the event of
further toxicity, a second-step dose reduction to 50% of the starting dose was
allowed. Treatment was not resumed until symptoms had resolved to grade 0
or 1. Once the capecitabine or 5-FU/LV dose had been reduced, it was not to be
increased at a later time.
Results
Patient population
Between November 1998 and November 2001, 1987 patients
(intention-to-treat population) were enrolled in 164 centers world-
wide. The safety population included all patients receiving at least
one dose of study drug and followed up for safety (n = 1967, com-
prising 993 patients randomized to capecitabine and 974 patients
randomized to 5-FU/LV). The treatment arms were well balanced
in terms of baseline prognostic factors (Table 1).
Safety profile
Table 2 lists the most frequent (≥10% of patients) treatment-
related adverse events of all grades. Patients receiving capecitabine
experienced significantly (P <0.001) less diarrhea (46% versus
64% with 5-FU/LV), nausea/vomiting (36% versus 51%), stomatitis
(22% versus 60%) and alopecia (6% versus 22%). In addition,
neutropenia, as a clinical adverse event requiring medical inter-
vention, was significantly less common with capecitabine versus
5-FU/LV (2% versus 8%; P <0.001). The only treatment-related
adverse event occurring more commonly with capecitabine was
hand–foot syndrome (62% versus 10% with 5-FU/LV; P <0.001).
Table 1. Patient baseline and disease characteristics
5-FU/LV, 5-fluorouracil–leucovorin; ECOG, Eastern Cooperative Oncology Group; N1, metastases 
in 1–3 regional lymph nodes; N2, metastases in ≥4 regional lymph nodes; CEA, carcinoembryonic 
antigen; ULN, upper limit of normal.
Capecitabine (n = 993) 5-FU/LV (n = 974)
Male/female (%) 54/46 54/46
Median age, years (range) 62 (25–80) 63 (22–82)
ECOG score: 0/1 (%) 85/15 85/15
Node status: N1/N2 (%) 69/30 71/29
Preoperative CEA values (%)
Normal 83 85
>1–≤2× ULN 6 5
>2× ULN 2 2
>5× ULN 1 <1
Missing 8 8
Table 2. Most common (≥10%) treatment-related adverse events (all grades)
5-FU/LV, 5-fluorouracil–leucovorin; NS, not significant.
Percentage of patients P value
Capecitabine (n = 993) 5-FU/LV (n = 974)
Diarrhea 46 64 <0.001
Nausea/vomiting 36 51 <0.001
Stomatitis 22 60 <0.001
Hand–foot syndrome 62 10 <0.001
Fatigue/asthenia 23 23 NS
Alopecia 6 22 <0.001
Abdominal pain 10 13 NS
Lethargy 10 9 NS
Anorexia 9 10 NS
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Figure 1 shows severe (grade 3 or 4) toxicities. Patients receiving
capecitabine experienced significantly less grade 3 or 4 stomatitis
(2% versus 14% with 5-FU/LV; P <0.001) and grade 3 or 4
neutropenia requiring medical intervention (0.6% versus 5%;
P <0.001). Febrile neutropenia/sepsis was also significantly less
common in patients receiving capecitabine (0.3% versus 3%;
P <0.001). As expected, grade 3 hand–foot syndrome was signifi-
cantly more common in the capecitabine arm (18% versus 0.6%;
P <0.001).
Early, severe (grade 3 or 4) fluoropyrimidine-related toxicities,
defined as the most clinically relevant types of adverse events
(i.e. gastrointestinal toxicities, infections, neutropenia and throm-
bocytopenia) occurring within the first 21 days of treatment are
shown in Table 3. Overall, significantly fewer patients receiving
capecitabine experienced early severe toxicities than patients
receiving 5-FU/LV (5.4% versus 17%, respectively; P <0.001).
Patients receiving 5-FU/LV also experienced more early grade 3
or 4 stomatitis (10% versus 1%), diarrhea (5% versus 3%) and
neutropenia (6% versus 1%) than those receiving capecitabine.
Laboratory abnormalities
Table 4 lists the most commonly occurring grade 3 or 4 laboratory
abnormalities in each treatment arm. Grade 3 or 4 neutropenia (as
a laboratory abnormality) was significantly less common in the
capecitabine arm compared with the 5-FU/LV arm (2% versus
26%; P <0.001). Also, the overall incidence of neutropenia (all
grades) was significantly lower in the capecitabine arm versus the
5-FU/LV arm (31% versus 61%; P <0.001). Grade 3 hyperbiliru-
binemia [defined as elevated bilirubin concentrations ≤3 times the
upper limit of normal (ULN)] was more common with capecitabine
Figure 1. Most common (>2%) treatment-related grade 3/4 adverse events.
Table 3. Incidence of early severe toxicities (i.e. grade 3 or 4 gastrointestinal toxicities, infections, neutropenia, 
and thrombocytopenia occurring within the first 21 days of treatment)a
aAn individual patient can have more than one specific grade 3 or 4 event.
bNeutropenia and thrombocytopenia recorded as grade 3 or 4 laboratory abnormalities.
cOther gastrointestinal toxicities and infections affecting two or less patients in either of the treatment arms.
5-FU/LV, 5-fluorouracil–leucovorin.
Capecitabine 5-FU/LV
<65 years 
(n = 596) (%)
≥65 years 
(n = 397) (%)
<65 years 
(n = 562) (%)
≥65 years
(n = 412) (%)
Any defined events 4.9 6.3 15.1 19.7
Stomatitis 0.7 1.8 7.7 12.1
Diarrhea 2.3 3.5 6.0 4.6
Neutropeniab 1.7 1.0 4.1 9.2
Thrombocytopeniab 1.7 1.8 0.2 0.2
Nausea 1.0 0.8 0.5 0.5
Vomiting 0.7 0.3 1.2 0.5
Abdominal pain 0.7 0.5 0.4 1.5
Intestinal obstruction 0.2 0.3 0.4 0.5
Febrile neutropenia 0 0 0.4 1.0
Other toxicitiesc 1.0 2.0 1.2 2.2
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(18.6% versus 5.9%). Similarly, grade 4 hyperbilirubinemia
(defined as elevated bilirubin concentrations >3 times ULN) was
more common with capecitabine (1.4% versus 0.3%; P <0.001).
The incidence of grade 3 or 4 abnormalities in ASAT and ALAT
in both treatment arms was, however, low (0.7% and 1.6%,
respectively, with capecitabine; and 0.3% and 0.6%, respectively,
with 5-FU/LV).
Impact of age on safety profile
The safety profile of capecitabine and 5-FU/LV were analyzed in
patients aged <65 and ≥65 years (Tables 5 and 6). Overall,
capecitabine showed a more favorable safety profile than 5-FU/
LV in both the younger and older patients, with less treatment-
related diarrhea, nausea, vomiting, stomatitis and neutropenia, but
more hand–foot syndrome (Table 5). For grade 3 or 4 adverse
events, patients aged <65 and ≥65 years receiving capecitabine
experienced less stomatitis and neutropenia, and more hand–foot
syndrome compared with the 5-FU/LV-treated patients (Table 6).
Older patients (≥65 years) receiving 5-FU/LV experienced a
higher incidence of early severe toxicities (gastrointestinal
toxicities, infections, neutropenia and thrombocytopenia) during
the first 21 days of treatment compared with the younger patients
(<65 years) (20% versus 15%, respectively) (Table 3). In contrast,
Table 4. Most frequently occurring (≥3%) grade 3 or 4 laboratory abnormalities
5-FU/LV, 5-fluorouracil–leucovorin; NS, not significant.
Percentage of patients P value
Capecitabine (n = 993) 5-FU/LV (n = 974)
Hyperbilirubinemia 20 6 <0.001
Lymphocytopenia 13 13 NS
Neutropenia 2 26 <0.001
Leucopenia 1 5 <0.001
Table 5. Incidence of most common (≥10%) treatment-related adverse events (all grades) according to age
5-FU/LV, 5-fluorouracil–leucovorin.
Capecitabine 5-FU/LV
<65 years (n = 596) (%) ≥65 years (n = 397) (%) <65 years (n = 562) (%) ≥65 years (n = 412) (%)
Diarrhea 42 52 65 63
Stomatitis 19 27 59 62
Nausea 32 34 44 49
Vomiting 13 16 18 21
Hand–foot syndrome 61 63 9 11
Fatigue 13 17 15 15
Abdominal pain 9 12 13 13
Neutropenia 2 3 10 7
Table 6. Analyses of most common (>2%) grade 3 or 4 adverse events by age group
aNeutropenia as a grade 3 or 4 laboratory abnormality.
5-FU/LV, 5-fluorouracil–leucovorin.
Capecitabine 5-FU/LV
<65 years (n = 596) (%) ≥65 years (n = 397) (%) <65 years (n = 562) (%) ≥65 years (n = 412) (%)
Diarrhea 10 13 13 13
Stomatitis 1 3 11 18
Hand–foot syndrome 16 20 <1 <1
Neutropeniaa 2 3 26 27
Nausea 2 1 2 1
Vomiting 2 1 2 2
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with capecitabine the incidence of early severe toxicities was
similar in patients aged ≥65 years and <65 years (4.9% versus
6.3%, respectively).
Dose modification and premature withdrawal
Dose reduction was required in 42% of patients receiving capecit-
abine compared with 44% of patients receiving 5-FU/LV. Median
time to first dose reduction was longer for patients receiving
capecitabine compared with 5-FU/LV (78 versus 41 days). Second-
level dose reductions (to <60% of the capecitabine starting dose
and <75% of the 5-FU/LV starting dose) were also more common
in the 5-FU/LV arm than the capecitabine arm (26% versus 13%);
median time to second-level dose reduction was longer for patients
receiving capecitabine (113 versus 57 days with 5-FU/LV).
The adverse events most commonly leading to dose modifi-
cation (including treatment interruption and dose reduction) were
hand–foot syndrome (31%) and diarrhea (15%) in the capecitabine
arm, and stomatitis (23%) and diarrhea (19%) in the 5-FU/LV arm
(Table 7).
Premature withdrawal was infrequent in both treatment arms. In
total, 84% of patients receiving capecitabine completed all eight
cycles of treatment (24 weeks) and 88% of patients on 5-FU/LV
received all six cycles (24 weeks). Table 8 shows the number of
patients starting each cycle of treatment. Premature withdrawal
due to adverse events occurred in 12% of patients receiving
capecitabine and 8% of those receiving 5-FU/LV.
There were three (0.3%) treatment-related deaths in the capecit-
abine arm, two patients aged <65 years (one due to multi-organ
failure on day 23, the other due to septic shock on day 22) and one
patient aged ≥65 years (due to pneumonia on day 91). There were
four deaths (0.4%) in the 5-FU/LV treatment arm, three patients
aged <65 years (one on day 16 after experiencing severe diarrhea
and vomiting, one due to respiratory arrest on day 69, and one due
to gastrointestinal hemorrhage on day 131) and one patient aged
≥65 years (due to bronchopneumonia on day 189). Overall, there
was a low incidence of all-cause, 60-day mortality, with five
deaths in the capecitabine arm (0.5%) and four in the 5-FU/LV
arm (0.4%).
Resource use: treatments for adverse events
Fewer patients receiving capecitabine required medications for
the treatment of adverse events (703 patients versus 768 patients
with 5-FU/LV). The most commonly prescribed treatments for
adverse events were loperamide, antibiotics and metoclopramide
(Table 9). Fewer patients receiving capecitabine required lopera-
mide (231 versus 372 with 5-FU/LV) and metoclopramide (141
versus 243 with 5-FU/LV), reflecting the significantly lower
incidences of diarrhea and nausea/vomiting in the capecitabine
Table 7. Adverse events commonly leading to treatment modification
aBoth dose reductions and treatment interruptions included.
5-FU/LV, 5-fluorouracil–leucovorin.
Treatment modificationa Treatment discontinuation
Capecitabine 
(n = 993) (%)
5-FU/LV 
(n = 974) (%)
Capecitabine 
(n = 993) (%)
5-FU/LV
(n = 974) (%)
Diarrhea 15 19 3 3
Hand–foot syndrome 31 <1 3 <1
Stomatitis 3 23 <1 2
Neutropenia 3 13 0 <1
Table 8. Number of patients starting each cycle
aMayo Clinic regimen arm included six cycles of treatment.
5-FU/LV, 5-fluorouracil–leucovorin.
Capecitabine (n = 993) [n (%)] 5-FU/LVa (n = 974) [n (%)]
Cycle 1 993 (100) 974 (100)
Cycle 2 965 (97) 936 (96)
Cycle 3 935 (94) 913 (94)
Cycle 4 920 (93) 894 (92)
Cycle 5 901 (91) 880 (90)
Cycle 6 886 (89) 862 (89)
Cycle 7 868 (87) –
Cycle 8 833 (84) –
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group. Fewer patients receiving capecitabine required treatment
with antibiotics (217 versus 289 with 5-FU/LV). The lower
incidence of neutropenia with capecitabine was reflected by less
frequent need for granulocyte colony-stimulating factor (G-CSF).
Seven patients receiving capecitabine required G-CSF compared
with 27 in the 5-FU/LV group.
Discussion
Capecitabine is a firmly established first-line treatment for meta-
static colorectal cancer, based on its superior antitumor activity
and improved safety profile compared with i.v. 5-FU/LV [12]. In
light of the improved convenience and patient acceptability of oral
capecitabine, the current study is being conducted to determine
whether capecitabine can replace i.v. 5-FU/LV as the standard
adjuvant treatment for Dukes’ C colon cancer. Efficacy data are
not expected until 2004, but the results of this planned safety
analysis demonstrate that capecitabine has an improved safety
profile in the adjuvant setting compared with bolus i.v. 5-FU/LV.
Furthermore, the improved safety profile of capecitabine in the
adjuvant setting mirrors that observed in the metastatic setting
[13].
As first-line treatment for metastatic colorectal cancer, capecit-
abine was associated with significantly lower incidences of diarrhea,
stomatitis, nausea, alopecia, neutropenia (including grade 3 or 4)
and febrile neutropenia/sepsis compared with 5-FU/LV (Mayo
Clinic regimen). Hand–foot syndrome occurred more frequently
with capecitabine. The improved safety profile of adjuvant
capecitabine versus 5-FU/LV is demonstrated by significantly
lower incidences of diarrhea, nausea/vomiting, stomatitis (including
grade 3 or 4), alopecia, neutropenia (including grade 3 or 4) and
febrile neutropenia/sepsis. The most common treatment-related
adverse event with adjuvant capecitabine is a cutaneous side
effect, hand–foot syndrome. Experience in the metastatic setting
shows that hand–foot syndrome is effectively managed by ade-
quate patient education, treatment interruption and, if necessary,
dose reduction, and rarely leads to treatment discontinuation or
hospitalization [13]. Hyperbilirubinemia is a known side effect of
oral fluoropyrimidines and rarely associated with clinical abnor-
malities [13]. Grade 3 or 4 hyperbilirubinemia was more common
in patients receiving capecitabine than in those receiving 5-FU/LV.
But elevated ASAT and ALAT concentrations were uncommon in
both treatment arms, suggesting that hyperbilirubinemia is not
associated with hepatobiliary dysfunction.
A low level of early severe toxicities, potentially leading to
treatment discontinuation or even death, is particularly important in
the adjuvant setting. In this study, patients receiving capecitabine
were three times less likely to experience severe early gastro-
intestinal toxicities, infections, neutropenia and thrombocyto-
penia compared with those patients receiving 5-FU/LV. These
data further confirm the favorable safety profile of capecitabine.
Colorectal cancer is more common in older patients so it is
important to note that capecitabine was equally well tolerated by
older and younger patients. In both subgroups, capecitabine was
associated with less diarrhea, nausea, vomiting, stomatitis and
neutropenia than 5-FU/LV. Patients aged ≥65 years in the capecit-
abine arm experienced a similar incidence of early severe toxicities
(gastrointestinal toxicities, infections, neutropenia and thrombo-
cytopenia) to the younger patients (aged <65 years), but in the
5-FU/LV arm, patients aged ≥65 years experienced a higher
incidence of early severe toxicities compared with patients aged
<65 years.
As previously demonstrated in the metastatic setting [18],
capecitabine improves medical-resource use compared with
5-FU/LV. Oral capecitabine is administered at home and patients
require fewer hospital visits compared with patients receiving i.v.
treatment. Administration of 5-FU/LV (Mayo Clinic regimen)
requires patients to attend the clinic/hospital for five consecutive
days during every 28-day treatment cycle. In addition, the
improved safety profile of capecitabine, particularly the signifi-
cantly lower incidences of diarrhea, nausea/vomiting and neutro-
penia, leads to a reduced need for medications to manage adverse
events.
Good tolerability is a particularly important consideration when
chemotherapy is administered in the adjuvant setting. A number
of ongoing trials are evaluating 5-FU/LV in combination with
irinotecan or oxaliplatin in the adjuvant setting. Recently, results
from the MOSAIC study evaluating bolus/infusional 5-FU/LV
and oxaliplatin (FOLFOX4) versus infusional 5-FU/LV (the de
Gramont regimen) as adjuvant treatment for patients with stage II
Table 9. Most frequently (≥10% of patients) administered treatments for adverse events
aBenzydamine is a mouthwash/spray for painful inflammatory conditions of oropharynx.
5-FU/LV, 5-fluorouracil–leucovorin.
No. of patients (%)
Capecitabine (n = 993) 5-FU/LV (n = 974)
Loperamide 231 (23) 372 (38)
Antibiotics 217 (22) 289 (30)
Metoclopramide 141 (14) 243 (25)
Paracetamol 97 (10) 107 (11)
Pyridoxine 152 (15) 20 (2)
Benzydaminea 25 (3) 108 (11)
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or III colon cancer were presented [19]. Although FOLFOX4
achieved a significant improvement in 3-year disease-free sur-
vival, this was at the expense of a higher incidence of grade 3 or 4
neutropenia, and 29% of patients experienced long-term (>1 year),
low-grade neurotoxicity. Therefore, with FOLFOX4 there is a
trade-off between improved outcomes and potential for short- and
long-term side effects. In addition, recent preliminary data from
the CALGB C89803 trial comparing weekly bolus irinotecan/
5-FU/LV with weekly 5-FU/LV (Roswell Park schedule) in the
adjuvant setting failed to show any failure-free (P = 0.88) or over-
all survival (P = 0.92) benefit associated with the combination arm
(letter from principal investigator to National Cancer Institute
Cooperative Group Investigators, 26 August 2003). Thus, further
studies are needed to establish the benefit of combination chemo-
therapy over fluoropyrimidine monotherapy.
The improved safety profile of capecitabine versus 5-FU/LV
observed in the current trial suggests that capecitabine is an attractive
agent to replace 5-FU/LV as the backbone of adjuvant combin-
ation treatment for further studies. A large international study has
shown that capecitabine in combination with oxaliplatin (XELOX)
is a highly active, first-line treatment for metastatic colorectal
cancer [20], achieving efficacy similar to that reported for
FOLFOX4 with a substantially lower incidence of neutropenia
(7% with XELOX versus 42–47% with FOLFOX4 [21, 22]).
XELOX is currently being evaluated versus bolus 5-FU/LV
(Mayo Clinic or Roswell Park regimen) as adjuvant treatment for
chemotherapy-naïve patients with Dukes’ C colon cancer.
Recruitment of 1850 patients for this trial has begun.
In summary, this analysis shows that from a safety perspective,
capecitabine can replace 5-FU/LV as the standard adjuvant treat-
ment for patients with colon cancer. The efficacy results from this
study are expected in 2004.
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